T 细胞治疗市场规模、份额、成长分析、按方式、按类型、按适应症、按最终用户、按地区 - 行业预测，2024-2031 年

2022年全球T细胞治疗市场规模为28.3亿美元，从2023年的38.3亿美元成长到2031年的430亿美元，在预测期间（2024-2031年）预计复合年增长率为35.3%。

癌症仍然是全球主要死亡原因之一，预计到 2040 年，癌症患者将增加 2,750 万人。儘管现有的治疗方法可以减缓疾病进展，但维持长期缓解仍然是一项挑战。相较之下，免疫疗法，尤其是 CAR-T、TCR 和 TIL 疗法等 T 细胞疗法，由于其副作用较少且能够有效靶向和消除癌细胞而受到关注。这种创新方法利用了人体免疫系统的力量，并将 T 细胞疗法定位为癌症治疗的创新解决方案。随着此类细胞疗法的发展不断加速，这一新兴领域有望成为生物製药产业最赚钱的市场之一。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 专利分析
• 案例研究

按治疗类型和复合年增长率分類的 T 细胞治疗市场规模（2024-2031）

• 市场概况
• CAR-T细胞疗法
• 肿瘤浸润淋巴细胞（TIL）疗法
• 基于 T 细胞受体 (TCR) 的治疗

T 细胞治疗市场规模：按方式及复合年增长率 (2024-2031)

• 市场概况
• 研究用途
• 临床使用

T 细胞治疗市场规模：依适应症及复合年增长率（2024-2031）

• 市场概况
• 造血系统恶性
  • 淋巴瘤
  • 白血病
  • 多发性骨髓瘤
• 固态肿瘤
  • 恶性黑色素瘤
  • 肺癌
  • 大肠直肠癌
  • 乳癌
• 感染疾病
  • COVID-19
  • HIV
• 自体免疫疾病
  • 类风湿性关节炎
  • 多发性硬化症

T 细胞治疗市场规模：依最终用户及复合年增长率（2024-2031）

• 市场概况
• 医院
• 癌症治疗中心
• 调查机构

T 细胞治疗市场规模：按地区及复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Novartis（Switzerland）
• Gilead Sciences（USA）
• Bristol-Myers Squibb（USA）
• Kite Pharma（USA）
• Juno Therapeutics（USA）
• Adaptimmune（UK）
• Bluebird Bio（USA）
• Cellectis（France）
• Bellicum Pharmaceuticals（USA）
• Sangamo Therapeutics（USA）
• Atara Biotherapeutics（USA）
• Autolus Therapeutics（UK）
• Immatics（Germany）
• Allogene Therapeutics（USA）
• Mustang Bio（USA）
• Celyad Oncology（Belgium）
• Genocea Biosciences（USA）
• Iovance Biotherapeutics（USA）

结论和建议

Global T-Cell Therapy Market size was valued at USD 2.83 billion in 2022 and is poised to grow from USD 3.83 billion in 2023 to USD 43.0 billion by 2031, growing at a CAGR of 35.3% during the forecast period (2024-2031).

Cancer remains one of the leading causes of mortality worldwide, with projections indicating an addition of 27.5 million cases by 2040, imposing heavy financial, emotional, and physical strains on individuals and healthcare systems alike. While existing treatment options can slow disease progression, achieving long-lasting remission remains a challenge. In response, immunotherapies, particularly T-cell therapies such as CAR-T, TCR, and TIL therapies, are gaining traction for their ability to effectively target and eliminate tumor cells with fewer side effects. This innovative approach harnesses the human immune system's power, positioning T-cell therapy as a transformative solution in cancer treatment. As the development of these cell therapies continues to accelerate, this emerging sector is poised to become one of the most lucrative markets in the biopharmaceutical industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global T-Cell Therapy Market Segmental Analysis

Global T-Cell Therapy Market is segmented by therapy type, modality, indication, end-user and region. Based on therapy type, the market is segmented into CAR T-cell therapy, tumor-infiltrating lymphocytes (TIL) therapy and t cell receptor (TCR)-based therapy. Based on modality, the market is segmented into research use and clinical use. Based on indication, the market is segmented into hematologic malignancies, solid tumors, infectious diseases and autoimmune diseases. Based on end-user, the market is segmented into hospitals, cancer treatment centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global T-Cell Therapy Market

The Global T-Cell Therapy market is being significantly driven by the recent FDA approvals of Yescarta, Kymriah, and Tecartus, prompting numerous companies to pivot from developing traditional protein and small-molecule therapeutics to focus on adoptive therapies as their core business strategy. This shift has led to a remarkable increase in the T-cell therapy market, bolstered by strategic investments from both public and private sectors. The burgeoning gene therapy landscape plays a crucial role, as these advancements enhance the efficacy of CAR-T therapies. Additionally, the integration of T-cell approaches in cancer immunotherapy, combined with substantial funding dedicated to CAR T-cell research, is expected to propel the market, particularly with an expanding clinical trial environment for various hematologic cancers.

Restraints in the Global T-Cell Therapy Market

The T-cell therapy market faces significant constraints primarily due to the limited effectiveness of CAR-T therapies in treating solid tumors, compounded by safety concerns arising from the highly immunosuppressive tumor microenvironment. These challenges hinder market expansion, prompting industry stakeholders to explore innovative strategies to overcome these obstacles. Efforts are being made to enhance the applicability of CAR-T treatments in solid tumors, which may subsequently widen their therapeutic impact and improve patient outcomes. As the sector evolves, addressing these limitations will be crucial for tapping into the full potential of T-cell therapies in various oncological applications.

Market Trends of the Global T-Cell Therapy Market

The Global T-Cell Therapy market is witnessing a notable trend towards the application of CAR T-cell therapies in the treatment of solid tumors, particularly in challenging cases such as diffuse midline glioma, a rare and aggressive pediatric cancer. Research highlights the potential of CAR T-cell treatment to significantly improve patient outcomes, with successful trials showing extended tumor eradication in animal models despite facing toxicity challenges. Intracerebroventricular (ICV) delivery methods are emerging as a safer, more efficient alternative to systemic administration, marking a pivotal shift in therapeutic strategies. This evolving landscape is expected to drive substantial growth in the T-Cell Therapy market, attracting investments and innovations tailored for solid tumor applications.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global T-Cell Therapy Market Size by Therapy Type & CAGR (2024-2031)

• Market Overview
• CAR T-Cell Therapy
• Tumor-Infiltrating Lymphocytes (TIL) Therapy
• T Cell Receptor (TCR)-Based Therapy

Global T-Cell Therapy Market Size by Modality & CAGR (2024-2031)

• Market Overview
• Research Use
• Clinical Use

Global T-Cell Therapy Market Size by Indication & CAGR (2024-2031)

• Market Overview
• Hematologic Malignancies
  • Lymphoma
  • Leukemia
  • Multiple Myeloma
• Solid Tumors
  • Melanoma
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
• Infectious Diseases
  • COVID-19
  • HIV
• Autoimmune Diseases
  • Rheumatoid Arthritis
  • Multiple Sclerosis

Global T-Cell Therapy Market Size by End-User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Cancer Treatment Centers
• Research Institutes

Global T-Cell Therapy Market Size & CAGR (2024-2031)

• North America (Therapy Type, Modality, Indication, End-User)
  • USA
  • Canada
• Europe (Therapy Type, Modality, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Modality, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Modality, Indication, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Modality, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bellicum Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atara Biotherapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immatics (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mustang Bio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celyad Oncology (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genocea Biosciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations